Moderna Inc. reported a larger-than-expected quarterly loss for the fourth quarter of 2024, with an earnings per share of -$2.91, missing estimates of -$2.68. Despite this, the company's revenue reached $966 million, surpassing the anticipated $942.8 million, though it represented a significant year-over-year decline of 66%. The majority of the revenue, $923 million, came from sales of its Covid-19 vaccine, which saw a decrease due to the earlier launch of the latest iteration in the previous year. Additionally, Moderna recorded a $238 million non-cash charge related to the termination of a manufacturing contract. The company's efforts to cut costs were evident, with a 27% reduction in expenses in 2024, and plans to reduce costs by an additional $1 billion in 2025. Moderna's shares ($MRNA) fell by 4.1% in premarket trading following the earnings release, contributing to a year-to-date drop of 23%. The company also provided guidance for 2025, expecting revenue between $1.5 billion and $2.5 billion, a reduction from previous estimates due to various market challenges. Furthermore, Moderna is facing regulatory hurdles with its norovirus vaccine trial being put on hold by the FDA over a reported case of Guillain-Barré syndrome, though the company does not anticipate this affecting the trial's efficacy readout timeline.